A detailed history of Stifel Financial Corp transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 102,377 shares of ABCL stock, worth $263,108. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,377
Previous 109,277 6.31%
Holding current value
$263,108
Previous $495,000 38.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.73 - $4.73 $18,837 - $32,637
-6,900 Reduced 6.31%
102,377 $303,000
Q1 2024

May 13, 2024

SELL
$4.29 - $5.97 $3,723 - $5,181
-868 Reduced 0.79%
109,277 $495,000
Q4 2023

Feb 12, 2024

BUY
$3.91 - $5.93 $177,991 - $269,945
45,522 Added 70.44%
110,145 $628,000
Q3 2023

Nov 13, 2023

SELL
$4.6 - $7.95 $14,673 - $25,360
-3,190 Reduced 4.7%
64,623 $297,000
Q2 2023

Aug 14, 2023

SELL
$5.66 - $7.59 $27,218 - $36,500
-4,809 Reduced 6.62%
67,813 $438,000
Q1 2023

May 12, 2023

SELL
$7.31 - $11.18 $14,334 - $21,923
-1,961 Reduced 2.63%
72,622 $547,000
Q4 2022

Feb 13, 2023

BUY
$9.48 - $14.52 $3,090 - $4,733
326 Added 0.44%
74,583 $755,000
Q3 2022

Nov 14, 2022

BUY
$9.2 - $13.68 $114,834 - $170,753
12,482 Added 20.21%
74,257 $734,000
Q2 2022

Aug 15, 2022

BUY
$5.72 - $10.65 $128,414 - $239,092
22,450 Added 57.09%
61,775 $658,000
Q1 2022

May 13, 2022

BUY
$7.46 - $14.14 $3,759 - $7,126
504 Added 1.3%
39,325 $383,000
Q4 2021

Feb 14, 2022

SELL
$12.99 - $17.73 $411,770 - $562,023
-31,699 Reduced 44.95%
38,821 $555,000
Q3 2021

Nov 15, 2021

BUY
$14.85 - $21.34 $720,447 - $1.04 Million
48,515 Added 220.47%
70,520 $1.41 Million
Q2 2021

Aug 13, 2021

BUY
$20.19 - $34.17 $297,519 - $503,529
14,736 Added 202.72%
22,005 $484,000
Q1 2021

May 14, 2021

BUY
$23.29 - $53.2 $169,295 - $386,710
7,269 New
7,269 $247,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $733M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.